Key result
Bisoprolol treatment for 4 months significantly increased right ventricular ejection fraction by 7.1% (95% CI 3.9-10.2; p=0.0001) in patients with chronic heart failure.
Why the study?
Does bisoprolol improve right ventricular ejection fraction in patients with chronic heart failure?
Cohort (n=30)
Does bisoprolol improve right ventricular ejection fraction in patients with chronic heart failure?
Mean Difference: 7.1 (95% CI 3.9–10.2)
p-value: p=0.0001
Short-term bisoprolol therapy significantly improves right ventricular ejection fraction in patients with chronic heart failure, paralleling improvements in left ventricular function.
May support bisoprolol for right ventricular function in chronic heart failure; hypothesis-generating, needs randomized confirmation.
Beta-blocker use improves left ventricular ejection fraction (LVEF) in patients with heart failure. A similar effect of b blockers on right ventricular function has been proposed, although the effect of bisoprolol, a highly selective b-1 blocker, on right ventricular function has not been assessed. This study investigated the short-term effect of bisoprolol on right ventricular function in chronic heart failure patients. A cohort of 30 heart failure patients who were not taking b blockers at baseline was studied prospectively. Right ventricular ejection fraction (RVEF) and LVEF were measured at both baseline and 4 months by radionuclide angiography. Bisoprolol was up-titrated during four monthly visits by a preestablished protocol to a target dose of 10 mg/d. The dose of vasodilators was not changed. Quality of life and brain natriuretic peptide level were assessed. Mean age was 62.7+/-14.3 years. Baseline RVEF was 30.7%+/-6.3% and baseline LVEF was 21.7%+/-9.4%. Mean bisoprolol dose reached was 5.3+/-3.9 mg daily. At 4 months, RVEF significantly increased by 7.1% (95% confidence interval, 3.9-10.2; p=0.0001) and LVEF also increased significantly by 7.9% (95% confidence interval, 4.0%-11.9%; p=0.0003). Quality-of-life score improved from 42.8 to 30.8 (p=0.047). No correlation was found between brain natriuretic peptide levels and RVEF. Bisoprolol treatment for 4 months resulted in a significant improvement of RVEF, which paralleled the improvement of LVEF.
No takes yet. Share an insight, caveat, or question.
Neto et al. (2004) conducted a cohort in chronic heart failure (n=30). Bisoprolol vs. Baseline was evaluated on Right ventricular ejection fraction (RVEF) (MD 7.1%, 95% CI 3.9-10.2, p=0.0001). Bisoprolol treatment for 4 months significantly increased right ventricular ejection fraction by 7.1% (95% CI 3.9-10.2; p=0.0001) in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: